反応式
Br[C:2]1[CH:38]=[CH:37][C:5]([O:6][CH2:7][CH2:8][O:9][C:10]2[N:15]=[CH:14][N:13]=[C:12]([NH:16][S:17]([C:20]3[CH:25]=[CH:24][C:23]([C:26]([CH3:29])([CH3:28])[CH3:27])=[CH:22][CH:21]=3)(=[O:19])=[O:18])[C:11]=2[C:30]2[CH:35]=[CH:34][C:33]([CH3:36])=[CH:32][CH:31]=2)=[CH:4][CH:3]=1.[CH2:39]([O:41]C([Sn](CCCC)(CCCC)CCCC)=C)[CH3:40].O1C[CH2:61][O:60][CH2:59][CH2:58]1.[F-].[K+]>C(OCC)(=O)C.C1C=CC(P(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.C1C=CC(P(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1.Cl[Pd]Cl>[C:26]([C:23]1[CH:22]=[CH:21][C:20]([S:17]([NH:16][C:12]2[C:11]([C:30]3[CH:35]=[CH:34][C:33]([CH3:36])=[CH:32][CH:31]=3)=[C:10]([O:9][CH2:8][CH2:7][O:6][C:5]3[CH:4]=[CH:3][CH:2]=[CH:38][CH:37]=3)[N:15]=[CH:14][N:13]=2)(=[O:19])=[O:18])=[CH:25][CH:24]=1)([CH3:29])([CH3:27])[CH3:28].[C:39]([C:2]1[CH:38]=[CH:37][C:5]([O:6][CH2:7][CH2:8][O:9][C:10]2[N:15]=[CH:14][N:13]=[C:12]([NH:16][S:17]([C:20]3[CH:25]=[CH:24][C:23]([C:26]([CH3:28])([CH3:27])[CH3:29])=[CH:22][CH:21]=3)(=[O:19])=[O:18])[C:11]=2[C:30]2[CH:35]=[CH:34][C:33]([CH3:36])=[CH:32][CH:31]=2)=[CH:4][CH:3]=1)(=[O:41])[CH3:40].[C:26]([C:23]1[CH:24]=[CH:25][C:20]([S:17]([NH:16][C:12]2[C:11]([C:30]3[CH:35]=[CH:34][C:33]([CH3:36])=[CH:32][CH:31]=3)=[C:10]([O:9][CH2:8][CH2:7][O:6][C:5]3[CH:37]=[CH:38][C:2]([C:61]([O:60][CH2:59][CH3:58])=[O:41])=[CH:3][CH:4]=3)[N:15]=[CH:14][N:13]=2)(=[O:19])=[O:18])=[CH:21][CH:22]=1)([CH3:29])([CH3:28])[CH3:27]参加物
反応物 4
生成物 3
試薬・触媒・溶媒 2
実験手順
A mixture of N-[6-{2-(4-bromophenoxy)ethoxy}-5-(4-methylphenyl)pyrimidin-4-yl]-4-tert-butylbenzenesulfonamide (600 mg), (1-ethoxyvinyl)tributyltin (680 mg), bis(triphenylphosphine)palladium (II) chloride (35.5 mg) and dioxane (24 ml) is refluxed for 18 hours. The mixture is diluted with ethyl acetate, and thereto is added 10% aqueous potassium fluoride solution, and the precipitated crystals are removed by filtration. The filtrate is extracted with ethyl acetate, and the ethyl acetate layer is washed, dried, and concentrated to dryness under reduced pressure. The residue is purified by silica gel column chromatography (solvent; n-hexane/ethyl acetate=5:1~3:1~1:1), and the obtained compounds are each recrystallized from ethyl acetate/diisopropyl ether to give 4-tert-butyl-N-{5-(4-methylphenyl)-6-(2-phenoxyethoxy)pyrimidin-4-yl}benzenesulfonamide (Compound A) (42 mg), N-[6-{2-(4-acetylphenoxy)ethoxy}-5-(4-methylphenyl)pyrimidin-4-yl]-4-tert-butylbenzenesulfonamide (Compound B) (242 mg) and 4-tert-butyl-N-[6-{2-(4-ethoxycarbonylphenoxy)ethoxy}-5-(4-methylphenyl)pyrimidin-4-yl]benzenesulfonamide (Compound C) (58 mg), respectively.
後処理
- temperatureis refluxed for 18 hours
- customthe precipitated crystals are removed by filtration
- extractionThe filtrate is extracted with ethyl acetate
- washthe ethyl acetate layer is washed
- customdried
- concentrationconcentrated to dryness under reduced pressure
- customThe residue is purified by silica gel column chromatography (solvent; n-hexane/ethyl acetate=5:1~3:1~1:1)
- customeach recrystallized from ethyl acetate/diisopropyl ether
出典と根拠
- ORDレコード
- ord-46a2349036204912b3e748e1dead945d
- 出典データセット
- uspto-grants-1998_03
- 特許番号
- US05728706
関連ノート
読み込み中…